ES2915023T3 - HER2 como un factor predictivo de respuesta al bloqueo dual de HER2 en ausencia de terapia citotóxica - Google Patents

HER2 como un factor predictivo de respuesta al bloqueo dual de HER2 en ausencia de terapia citotóxica Download PDF

Info

Publication number
ES2915023T3
ES2915023T3 ES16809752T ES16809752T ES2915023T3 ES 2915023 T3 ES2915023 T3 ES 2915023T3 ES 16809752 T ES16809752 T ES 16809752T ES 16809752 T ES16809752 T ES 16809752T ES 2915023 T3 ES2915023 T3 ES 2915023T3
Authority
ES
Spain
Prior art keywords
her2
therapy
patient
chemotherapy
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16809752T
Other languages
English (en)
Spanish (es)
Inventor
Aparicio Aleix Prat
Castan Javier Cortes
Cussac Antonio Llombart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fund Solti
Hospital Clinic de Barcelona
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana FISABIO
Original Assignee
Fund Solti
Hospital Clinic de Barcelona
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana FISABIO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Solti, Hospital Clinic de Barcelona, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana FISABIO filed Critical Fund Solti
Application granted granted Critical
Publication of ES2915023T3 publication Critical patent/ES2915023T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES16809752T 2016-12-07 2016-12-07 HER2 como un factor predictivo de respuesta al bloqueo dual de HER2 en ausencia de terapia citotóxica Active ES2915023T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/080056 WO2018103834A1 (en) 2016-12-07 2016-12-07 Her2 as a predictor of response to dual her2 blockade in the absence of cytotoxic therapy

Publications (1)

Publication Number Publication Date
ES2915023T3 true ES2915023T3 (es) 2022-06-20

Family

ID=57543006

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16809752T Active ES2915023T3 (es) 2016-12-07 2016-12-07 HER2 como un factor predictivo de respuesta al bloqueo dual de HER2 en ausencia de terapia citotóxica

Country Status (5)

Country Link
US (1) US11851709B2 (https=)
EP (1) EP3551761B1 (https=)
JP (1) JP7377713B2 (https=)
ES (1) ES2915023T3 (https=)
WO (1) WO2018103834A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232057A1 (en) * 2020-05-12 2021-11-18 Institut D'investigacions Biomediques August Pi Isunyer (Idibaps) Methods for breast cancer treatment and prediction of therapeutic response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203015A1 (en) * 2008-02-13 2009-08-13 Celera Corporation Multiplex assays for hormonal and growth factor receptors, and uses thereof
NZ617520A (en) * 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US20100151463A1 (en) 2008-09-05 2010-06-17 Baehner Frederick L Method for Determining the Likelihood of Response to HER2 Inhibitors
WO2011031982A1 (en) 2009-09-10 2011-03-17 Myriad Genetics, Inc. Methods and compositions for predicting cancer therapy response
WO2011109637A1 (en) * 2010-03-03 2011-09-09 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers

Also Published As

Publication number Publication date
WO2018103834A1 (en) 2018-06-14
JP7377713B2 (ja) 2023-11-10
EP3551761A1 (en) 2019-10-16
US20190338368A1 (en) 2019-11-07
EP3551761B1 (en) 2022-03-16
US11851709B2 (en) 2023-12-26
JP2020500543A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
Jensen et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
Lamb et al. Hormone receptors in breast cancer: more than estrogen receptors
Yamauchi et al. When is a tumor marker ready for prime time? A case study of c-erb B-2 as a predictive factor in breast cancer
Sung et al. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma
Tobin et al. The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer
Saxena et al. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective
Leslie et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study
JP5656406B2 (ja) 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
Chen et al. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer
US20130217721A1 (en) Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
RU2605282C2 (ru) Биомаркеры на основе опухолевой ткани для комбинированной терапии бевацизумабом
TWI567391B (zh) 辨識早期肺腺癌病患之次群組之生物標記
Corte et al. Cytosolic levels of TFF1/pS2 in breast cancer: their relationship with clinical–pathological parameters and their prognostic significance
Raue et al. Long-term follow-up in medullary thyroid carcinoma patients
ES2915023T3 (es) HER2 como un factor predictivo de respuesta al bloqueo dual de HER2 en ausencia de terapia citotóxica
JP2015525881A (ja) 乳癌における予測マーカーとしてのＥＲα／Ｓｒｃ／ＰＩ３Ｋ複合体の検出
US20230160016A1 (en) Methods of selecting a treatment for cancer patients
KR101952649B1 (ko) Lrp-1을 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물
Mamounas et al. A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42
Xu et al. Overexpression of SRC‐3 promotes esophageal squamous cell carcinoma aggressiveness by enhancing cell growth and invasiveness
Mitchell et al. Individualization of adjuvant therapy after radical prostatectomy for clinically localized prostate cancer: current status and future directions
Özdemir et al. Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUVmax in Breast Cancer
US20170044627A1 (en) Six-Gene Biomarker of Survival and Response to Platinum Based Chemotherapy in Serious Ovarian Cancer Patients
Ezzibdeh et al. Neoadjuvant Immunotherapy in Non-melanoma Skin Cancers of the Head and Neck
Irshad et al. Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer